Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors
Study Information
Alliance Study ID: CALGB-9661
NCT Study ID (ClinicalTrials.gov): NCT00002994
Alliance Committee: Experimental Therapeutics
Disease or Cancer Type: Solid Tumors
Alliance Study Chair: Gini Fleming, MD
Status: COMPLETED
Study Description
RATIONALE: Interleukin-2 may stimulate a person’s white blood cells to kill solid tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
PURPOSE: Pilot study to examine the effectiveness of interleukin-2 plus monoclonal antibody in treating patients who have solid tumors.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information